Search

The outcomes of 293 patients with leukemia undergoing HLA-identical sibling (n = 158) or related HLA-mismatched (n = 135) hematopoietic cell transplantation (HCT) performed during the same time period were compared. Patients received BUCY2 in HLA-identical sibling HCT or BUCY2 + ATG in mismatched HCT as conditioning regimens, followed by unmanipulated marrow and/or peripheral blood (PB) transplantation. All patients achieved full engraftment. The cumulative incidences of grades II to IV acute graft-versus-host disease (aGVHD) in the matched and mismatched cohorts were 32% (CI, 25%-39%) versus 40% (CI, 32%-48%, P = .13), respectively, with the relative risk (RR) = 0.64 (95% CI, 0.43-0.94), P = .02. The incidence of chronic GVHD did not differ significantly between the cohorts (P = .97). Two-year incidences of treatment-related mortality and relapse for matched versus mismatched were 14% (range, 9%-20%) versus 22% (range, 15%-29%) with P = .10 and 13% (range, 8%-19%) versus 18% (range, 10%-27%) with P = .40, respectively. Two-year adjusted leukemia-free survival (LFS) and overall survival were 71% (range, 63%-78%) versus 64% (range, 54%-73%) with P = .27 and 72% (range, 64%-79%) versus 71% (range, 62%-77%) with P = .72, respectively. Multivariate analyses showed that only advanced disease stage and a diagnosis of acute leukemia had increased risk of relapse, treatment failure, and overall mortality. In summary, HCT performed with related HLA-mismatched donors is a feasible approach with acceptable outcomes.

Introduction To study the correlation of chemokine receptors expression on T lymphocyte subsets in recipients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with acute graft-versus-host disease (acute GVHD). Methods Forty-four recipients of family donor allogeneic hematopoietic stem cell transplantation were included in this study. According to the severity of acute GVHD, the recipients were divided into Grade II-IV acute GVHD group (n=16) and Grade 0-I acute GVHD group (n=28). Additionally,fifty healthy donors were also included in this study as the control group (n=50). The expression of chemokine receptors (CCR2,CCR5,CCR6,CCR7,CCR9 and CXCR3) on CD4+ and CD8+T cells in the peripheral blood after transplantation were detected using flow cytometry (FCM) respectively. The differences of the chemokine receptors expression between each group were compared. Results In both Grade 0-I acute GVHD group (on the 30th day after transplantation) and Grade II-IV acute GVHD group (at the peak of GVHD), CCR5 expression was significantly higher than that in the control group (p Conclusions Chemokine receptors on T cell subsets are involved in the pathogenesis of acute GVHD. Expression of chemokine receptors can be used as a powerful marker for early diagnosis and differential diagnosis of acute GVHD. And targeting chemokine receptors might be the new direction of prevention and treatment of acute GVHD. Disclosures: No relevant conflicts of interest to declare.